Edison Investment Research - Sygnis AG (LIO1) Update: Rights issue to fund market development

Report

Edison Investment Research

Update: Rights issue to fund market development

Sygnis sells its own-brand TruePrime and SunScript kits through its website and an international distributor network. A rights issue for â‚¬6.7m plus a â‚¬0.6m debt conversion was announced on 17 November. This will allow Sygnis to develop its brand, extend its product range of kits and enter the crucial US market. Kits may also be sold as OEM products for next-generation sequencing. A kit for cell-free DNA â€œliquid biopsyâ€ analysis, a high growth area, is planned for 2016. Cash at 30 September was â‚¬0.6m with a â‚¬0.3m loan payment due by the year end.

27/11/2015 10 EN

Underlying

Sygnis AG

See profile

Frankfurt Stock Exchange

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

GBC AG

Sygnis AG - Research Report (Anno) - 18.06.18

SYGNIS AG, headquartered in Heidelberg, is a life sciences company listed on the Prime Standard of the Deutsche Börse. The company focuses on the development and marketing of innovative molecular biology technologies in the NGS (next-generation sequencing) and the immuno-diagnostic sector. Its most important products currently on the market are TruePrimeTM (DNA amplification), SunScriptTM (transcribing RNA into DNA), RunBlue (DNA and protein separation and purification), Lightning Link (DNA and protein labeling) and CaptsureTM (biomarker capture) which are sold both through their own marketing...

June 18, 2018 June 18, 2018 21 EN

GBC AG

Sygnis AG - Researchstudie (Anno) - 18.06.18

Die SYGNIS AG ist spezialisiert auf die Entwicklung und Vermarktung von proprietären Technologien und bietet eine breite Palette verschiedener kommerzieller Produkte, die die wichtigsten Herausforderungen in der Molekularbiologie adressieren. Mit dem Erwerb der Expedeon Holdings, Ltd. Mit Sitz in Cambridge, Großbritannien, im Juli 2016 hat SYGNIS sein Produktportfolio um den Bereich Proteomik ergänzt. Durch diese bedeutende Erweiterung des Produktportfolios deckt SYGNIS nun den gesamten Arbeitsprozess der Molekularbiologie ab. Zudem hat SYGNIS im Dezember 2016 den profitablen US-Anbieter für L...

June 18, 2018 June 18, 2018 21 DE

GBC AG

Organic and Acquisitive Growth in Sales and Results; Critical Mass Reached for Sales Success; High Upside Potential Present

SYGNIS AG, headquartered in Heidelberg, is a life sciences company listed on the Prime Standard of theDeutsche Börse. The company focuses on the development and marketing of innovative molecular biologytechnologies in the NGS (next-generation sequencing) sector. Its most important products currently on themarket are TruePrimeTM (DNA amplification), SunScriptTM (transcribing RNA into DNA), RunBlue (DNA andprotein separation and purification) and Lightning Link (DNA and protein labeling) which are sold boththrough their own marketing and by non-exclusive sales partners. Other products (e.g., DNA...

EUR 162.86

November 8, 2017 November 8, 2017 18 EN

S&U - The time to look ahead

In line with earlier guidance, S&U reported H125 PBT of £12.8m, a significant decline versus H124 but an improvement versus H224. Customer repayment collections and earnings in the motor finance business were materially affected by the temporary restrictions agreed with the Financial Conduct Authority (FCA). These have since been lifted, and while regulatory discussions are ongoing, this is an important step towards the strong recovery in motor finance earnings that we forecast. Meanwhile, as previously reported, the property lending division continues to perform strongly, with a positive outl...

5h / 3m 5h / 3m 1 EN

Pedro Fonseca

Pedro Fonseca

Diverse Income Trust (The) - Could be the time for UK equities to shine

The Diverse Income Trust (DIVI) is a member of the 18-strong AIC UK Equity Income sector. It has a differentiated multi-cap income strategy and therefore its performance can differ meaningfully from those of its peers. Managers Gervais Williams and Martin Turner at Premier Miton Investors are very bullish on the outlook for UK stocks, which they believe can outperform overseas mainstream equity indices due to very attractive valuations and income prospects. They note that with global profit margins at all-time highs and increased geopolitical tensions, there could be a change in investor behav...

October 14, 2024 October 14, 2024 1 EN

Richard Williamson

Richard Williamson

Altron - Strong earnings growth in H125

Altron has provided an H125 trading update pointing to a more than doubling of headline EPS from continuing operations and an even larger increase in reported EPS. Having restated comparatives to reflect the move of Altron Document Solutions back to continuing operations, the improving performance of the remaining discontinued operation has become clearer, showing significantly reduced losses year-on-year. We maintain our forecasts pending the H125 results on 4 November.

October 14, 2024 October 14, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Rights issue to fund market development

Sygnis AG - Research Report (Anno) - 18.06.18

Sygnis AG - Researchstudie (Anno) - 18.06.18

Organic and Acquisitive Growth in Sales and Results; Critical Mass Reached for Sales Success; High Upside Potential Present

S&U - The time to look ahead

Diverse Income Trust (The) - Could be the time for UK equities to shine

Altron - Strong earnings growth in H125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe